Ferroptosis Blockade Improves Liver and Lung Graft Function : Cell | May 2026

Introduction

Ischemia–reperfusion injury (IRI) remains a major barrier in organ transplantation and contributes significantly to graft dysfunction, early allograft injury and organ discard. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has recently emerged as a key mechanism underlying tissue injury during ischemia and reperfusion.

Problem Statement

Despite increasing recognition of ferroptosis in transplant-associated injury, no clinically applicable therapies currently target this pathway. Existing ferroptosis inhibitors have been limited by poor pharmacokinetics and inadequate translational potential, while the precise temporal dynamics of lipid peroxidation during human transplantation remain incompletely characterized.

Summary

This landmark translational study identifies ferroptosis as a major therapeutic target in transplantation and introduces FXT-001 as a first-in-class drug-like ferroptosis inhibitor with promising clinical applicability. The investigators demonstrated that lipid peroxidation rapidly peaks within the first hour after graft reperfusion in human liver transplantation and correlates with severe ischemia–reperfusion injury. FXT-001 combines radical-trapping antioxidant activity with iron-binding capacity, enabling dual suppression of lipid peroxidation and ferroptotic cell death. Mechanistic studies showed preferential localization of FXT-001 within mitochondria and endolysosomal compartments, where it modulates subcellular iron handling and prevents membrane lipid radical propagation. In clinically relevant porcine liver donation-after-circulatory-death models, FXT-001 significantly reduced hepatocellular injury markers, improved glucose metabolism and preserved choleretic function during ex situ reperfusion. Parallel experiments in porcine and declined human donor lungs demonstrated reduced edema formation, lower extravascular lung water and improved graft compliance following ferroptosis inhibition. Importantly, the study also developed next-generation analogues, FXT-002 and FXT-003, with improved pharmacokinetic and safety profiles while retaining potent ferroptosis inhibition. The findings position ferroptosis inhibition as a potentially transformative strategy not only in transplantation but also across a broad spectrum of ischemia-associated conditions including myocardial infarction, stroke and vascular surgery. Overall, this work provides one of the strongest translational demonstrations to date that pharmacologic ferroptosis blockade can meaningfully improve organ preservation and graft function in human-relevant systems.